SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
InflaRx Reports Q2 2020 Financial & Operating Results
* Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-cause mortality rate * Completed end-of-Phase II meeting wi
GlobeNewswire · 4d ago
InflaRx reports Q2 results
Seeking Alpha · 4d ago
Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock?
Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.
Zacks · 07/24 12:55
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/23 14:43
InflaRx to launch late-stage IFX-1 study in COVID-19-induced pneumonia
Despite underwhelming preliminary data from an earlier study, InflaRx (NASDAQ:IFRX) initiates Phase III trial evaluating IFX-1 in severe COVID-19-induced p
seekingalpha · 07/21 17:29
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject.
GlobeNewswire · 07/21 11:30
InflaRx Sees Hammer Chart Pattern: Time to Buy?
InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.
Zacks · 07/09 11:33
Hedge Funds Are Buying InflaRx N.V. (IFRX)
Insider Monkey · 06/25 21:05
CLIR, IDEX, ENPH and BBI among midday movers
Seeking Alpha - Article · 06/17 16:41
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
GlobeNewswire · 06/17 12:30
NCLH, DKNG among premarket losers
Seeking Alpha - Article · 06/17 12:18
InflaRx reports underwhelming data from study of IFX-1 in COVID-19
Seeking Alpha - Article · 06/17 12:11
BTIG Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $12
BTIG analyst Dae Gon Ha initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $12.
Benzinga · 06/17 10:23
InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions
Zacks · 06/11 13:30
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
Zacks · 05/29 16:10
34 Stocks Moving in Friday's Pre-Market Session
Benzinga · 05/29 11:15
Europe Equities Are Hot on Stimulus Optimism: 5 Picks
Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.
Zacks · 05/28 12:31
Raymond James Maintains Outperform on InflaRx, Raises Price Target to $20
Raymond James maintains InflaRx (NASDAQ:IFRX) with a Outperform and raises the price target from $10 to $20.
Benzinga · 05/21 17:44
InflaRx Shares Rebound From Low, Turn Positive; Hearing Raymond James Raises Price Target From $10 To $20
Benzinga · 05/21 17:28
InflaRx EPS beats by $0.20
InflaRx (NASDAQ:IFRX): Q1 GAAP EPS of -€0.32 beats by €0.20. Cash, cash equivalents and financial assets of approximately €108M.  Shares +1.4%. Press Relea
seekingalpha · 05/21 16:33